Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Multicenter, Randomized, Double Blind, Parallel Group Study Followed by Dose Blind Period and Open Label Follow Up to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Trial Profile

A Phase 3 Multicenter, Randomized, Double Blind, Parallel Group Study Followed by Dose Blind Period and Open Label Follow Up to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms CIMPASI-1
  • Sponsors UCB

Most Recent Events

  • 13 Dec 2022 Results of pooled analysis from CIMPASI-1 and CIMPASI-, assessing 3-year quality of life outcomes for patients treated with Certolizumab Pegol, published in the Dermatology and Therapy
  • 03 Dec 2021 Results of pooled analysis from (CIMPASI-1 AND CIMPASI-2) studies presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
  • 11 Jul 2020 Results of pooled analysis from CIMPASI-1and CIMPASI-2, assessing three-year efficacy of Certolizumab-pegol in Plaque-psoriasis, published in the British Journal of Dermatology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top